J&J
J&J appoints chief design officer
March 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ernesto Quinteros, J&J, JJ, belkin, design
Johnson & Johnson has reached outside of its industry and into the design and technology realm with its latest appointment. …
GSK tops drug approval rates
March 7, 2014Medical Communications, Sales and Marketing FDA, GSK, J&J, JJ, Merck, Sanofi, ep, evaluate pharma, lilly, nme
GlaxoSmithKline is riding high when it comes to the approval of new medicines but US firm Lilly is falling behind. …
J&J reveals more on transparency policy
February 3, 2014Medical Communications, Research and Development, Sales and Marketing Goldacre, J&J, JJ, alltrials, johnson, transparency, yoda
Johnson & Johnson’s pharma subsidiary Janssen has given Pharmafile more details on its new transparency policy, which will see both …
J&J: we’re proud to top social media leaderboard
January 27, 2014Medical Communications, Sales and Marketing IMS, J&J, JJ, Janssen, digital, epatient, pharma
Johnson & Johnson says recognising the rise of the ePatient and being willing to share its corporate plans with the …
J&J profits up amid drug gains
January 23, 2014Sales and Marketing FDA, J&J, JJ, Remicade, Zytiga, olysio, q4
Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …
J&J tops social media leaderboard
January 22, 2014Medical Communications, Research and Development, Sales and Marketing Facebook, IMS, J&J, JJ, Twitter, You Tube, social media
A new report has found that Johnson & Johnson is the most engaged pharma company when it comes to using …
J&J to sell division for $4.1 billion
January 20, 2014Sales and Marketing Diagnostics, J&J, JJ, carlyle, ocd, ortho-clinical
Johnson & Johnson has been offered $4.15 billion by private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics …
€16 million fines for J&J and Novartis
December 12, 2013Medical Communications, Sales and Marketing EU, J&J, JJ, Novartis, Sandoz, fentanyl, fines
The European Commission has slapped multi-million euro fines on Johnson & Johnson and Novartis for what it says were ‘shocking’ …
J&J chooses UK as a new hub to ‘listen’ for innovation
December 10, 2013Research and Development, Sales and Marketing J&J, JJ, UK, innovation, research
Johnson & Johnson has chosen the UK as its formal European hub after announcing the creation of five new sites …
Cancer app takes top prize in Janssen digital awards
November 22, 2013Medical Communications, Sales and Marketing Cancer, J&J, JJ, app, digital, px healthcare
A start-up firm established by medical scientists that develops mobile apps for cancer patients has taken first place in the …
Merck and J&J invest in Chinese manufacturing
November 18, 2013Manufacturing and Production J&J, JJ, Merck, manufacturing
Merck KGaA and Johnson & Johnson have both announced new manufacturing projects in China, suggesting investigations into corruption by the …
J&J ‘to pay out $4 billion’ in fresh legal case
November 14, 2013Sales and Marketing J&J, JJ, Risperdal, fines, hip replacement
Johnson & Johnson is set to pay up to $4 billion to settle thousands of legal cases related to patients …
J&J hit with $2.2 billion fine
November 5, 2013Sales and Marketing J&J, JJ, Janssen, Risperdal, antipsychotic, fine
Johnson & Johnson has admitted promoting its big-selling antipsychotic drug Risperdal off-label, costing the firm $2.2 billion in fines. The …
Former FDA commissioner joins J&J
October 16, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, J&J, JJ
Johnson & Johnson has announced that ex-FDA commissioner Mark McClellan has been appointed to its Board of directors. Dr McClellan …
Latest content
